<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24068142</article-id>
      <article-id pub-id-type="pmc">3760946</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20131948</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cutaneous mucinosis in mixed connective tissue disease<xref ref-type="fn" rid="fn01">*</xref></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Mucinose cut&#xE2;nea na doen&#xE7;a mista do tecido conjuntivo</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Favarato</surname>
            <given-names>Maria Helena Sampaio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Assad</surname>
            <given-names>Ana Paula Luppino</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miranda</surname>
            <given-names>Sofia Silveira de Castro</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Halpern</surname>
            <given-names>Ilana</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caleiro</surname>
            <given-names>Maria Teresa Correia</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fuller</surname>
            <given-names>Ricardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> Rheumatologist, Staff Physician, Internal Medicine Department,
University of S&#xE3;o Paulo (USP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff02"><label>2</label> Rheumatologist; Rheumatology Department, University of S&#xE3;o Paulo (USP)
- S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff03"><label>3</label> Pathologist, Dermatopathology Division, Department of Dermatology,
University of S&#xE3;o Paulo Teaching Hospital (USP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff04"><label>4</label> Staff Physician, Rheumatology Department, University of S&#xE3;o Paulo (USP)
- S&#xE3;o Paulo (SP), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>MAILING ADDRESS:</bold> Ana Paula Luppino Assad, Faculdade de Medicina da
Universidade de S&#xE3;o Paulo. Av. Dr. Arnaldo, 455, 3&#xBA; andar, sala 3131, Cerqueira C&#xE9;sar
01246903 - S&#xE3;o Paulo - SP Brazil E-mail: <email>anastoamaro@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>4</issue>
      <fpage>635</fpage>
      <lpage>638</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>6</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Cutaneous mucinosis is a group of conditions involving an accumulation of mucin or
glycosaminoglycan in the skin and its annexes. It is described in some connective
tissue diseases but never in association with mixed connective tissue disease. This
report concerns two cases of cutaneous mucinosis in patients with mixed connective
tissue disease in remission; one patient presented the papular form, and the other
reticular erythematous mucinosis. These are the first cases of mucinosis described in
mixed connective tissue disease. Both cases had skin lesions with no other clinical
or laboratorial manifestations, with clinical response to azathioprine in one, and to
an association of chloroquine and prednisone in the other.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A mucinose cut&#xE2;nea &#xE9; um grupo de condi&#xE7;&#xF5;es em que h&#xE1; um ac&#xFA;mulo de mucina ou
glicosaminoglicanos na pele e seus anexos. &#xC9; descrita em algumas doen&#xE7;as do tecido
conjuntivo, porem nunca em associa&#xE7;&#xE3;o com doen&#xE7;a mista do tecido conjuntivo.
Relatamos dois casos de mucinose cut&#xE2;nea em pacientes com doen&#xE7;a mista do tecido
conjuntivo em remiss&#xE3;o, um apresentava-se sob a forma papular e outro sob a forma
reticular eritematosa de mucinose. Estes s&#xE3;o os primeiros casos de mucinose descritos
na doen&#xE7;a mista do tecido conjuntivo. Ambos os casos apresentaram o quadro cut&#xE2;neo de
modo isolado, sem nenhuma outra manifesta&#xE7;&#xE3;o cl&#xED;nico-laboratorial, havendo resposta &#xE0;
azatioprina em um e &#xE0; cloroquina associada a prednisona no outro.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Autoimmune diseases</kwd>
        <kwd>Lupus erythematosus, cutaneous</kwd>
        <kwd>Mixed connective tissue disease</kwd>
        <kwd>Mucinoses</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Cutaneous mucinosis is a group of conditions involving an accumulation of mucin or
glycosaminoglycan (GAG) in the skin and its annexes. It can occur in some diffuse
connective tissue diseases (DCTD) such as lupus erythematosus, but to the best of our
knowledge it has never before been reported in association with mixed connective tissue
disease (MCTD). </p>
    </sec>
    <sec>
      <title>CASE REPORTS</title>
      <p><bold>CASE 1:</bold> A female patient, 44-years-old, diagnosed with MCTD (Kasukawa's
classification criteria) for eight years. She had Raynaud's phenomenon, swollen hands,
polyarthritis, photosensitivity, esophageal ectasia, leukopenia, lymphopenia,
predominantly axonal peripheral sensorimotor polyneuropathy, sensorineural hearing loss
and anterior uveitis. Anti-RNP antibodies titers were 1/1200 (haemaglutination). The
patient remained stable for over one year taking azathioprine (1.5 mg/ kg / day) and
when joint activity initiated was treated with prednisone 10 mg/ day and leflunomida,
with improvement (<xref ref-type="fig" rid="f01">Figure 1</xref>). A month later she
noticed papules on the neck, back and face, which were biopsied. The histopathology
analysis revealed a mild lymphocytic infiltrate in lymphocytic perivascular and
periadnexal areas in the superficial dermis, with some melanophages and collagen fibers
dissociation (<xref ref-type="fig" rid="f02">Figure 2</xref>). The PAS showed focal
increase of the basal layer of the epidermis. The deposition of mucin was confirmed by
<italic>Alcian-Blue </italic>staining. The epidermis was normal. Immunofluorescence
showed no deposition of C3, anti-IgM, anti-IgG or anti-IgA antibodies. Histopathological
findings were therefore consistent with cutaneous papular mucinosis. The appearance of
this skin condition occurred independently of other manifestations of MCTD. The dose of
azathioprine was increased to 2mg/kg/day. This led to an improvement of the lesions.</p>
      <fig id="f01" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Case 1 - papules on the back</p>
        </caption>
        <graphic xlink:href="abd-88-0635-g01"/>
      </fig>
      <fig id="f02" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>A</bold> and <bold>C</bold>: Histopathology analysis: mild lymphocytic
infiltrate in superficial dermis, and collagen fibers dissociation, with normal
epidermis. <bold>B</bold> and <bold>D</bold>: The deposition of mucin was
confirmed by Alcian-Blue staining. <bold>A</bold> (100X); <bold>B</bold>
(200X); <bold>C</bold> and <bold>D</bold>(400X)</p>
        </caption>
        <graphic xlink:href="abd-88-0635-g02"/>
      </fig>
      <p><bold>CASE 2:</bold> A 42-year-old male, diagnosed with MCTD (Kasukawa's classification
criteria) for eight years. He had Raynaud's phenomenon, hand swelling, pleurisy,
lymphadenopathy, arthritis, myopathy and anti-RNP antibodies titers 1/6400
(haemaglutination. The patient remained clinically stable for more than seven months
with prednisone 15mg/day and azathioprine 2.0 mg/ kg / day when he presented
erythematous-violaceous indurated mildly pruritic and painless lesions in the face,
trunk and upper limbs (<xref ref-type="fig" rid="f03">Figure 3</xref>). As there were no
other signs of MCTD disease activity, the dose of prednisone was reduced to 7.5 mg/ day
and azathioprine was discontinued. Histopathological analysis of papules of the trunk
showed epidermal parakeratosis and hyperorthokeratosis. Perivascular, interstitial and
periadnexal lymphocytic inflammatory infiltrate appeared in the dermis (predominantly
the former). The <italic>alcian-blue </italic>and the PAS staining revealed interstitial
mucinosis in the reticular dermis. Chloroquine diphosphate was introduced (250 mg/ day)
and the prednisone dose was increased to 20 mg/ day, with improvement of the
lesions.</p>
      <p>
        <fig id="f03" fig-type="other" orientation="portrait" position="float">
          <label>FIGURE 3</label>
          <caption>
            <p>Case 2: erythematous-violaceous indurated mildly pruritic and painless lesions
on trunk</p>
          </caption>
          <graphic xlink:href="abd-88-0635-g03"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Cutaneous mucinosis covers a heterogeneous group of diseases involving a diffuse and/ or
focal mucin accumulation in the skin and its annexes.<sup><xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B02">2</xref></sup>The diseases can
be classified in two groups: primary cutaneous mucinoses that manifest with clinical
dermatologic applications (e.g. lichen myxedema, reticular erythematous mucinosis and
scleromixedema), and mucinosis associated with other diseases,<sup><xref ref-type="bibr" rid="B02">2</xref></sup>including certain endocrinopathies, especially thyroid
diseases, toxic diseases (toxic oil syndrome), Eosinophilia-Myalgia Syndrome,
nephrogenic fibrosing dermopathy, DCTD and cancer.<sup><xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B02">2</xref>,<xref ref-type="bibr" rid="B03">3</xref></sup></p>
      <p>Lupus erythematosus (LE) is a rheumatic disease most often associated with secondary
mucinosis (cutaneous mucinosis can occur in up to 1.5% of LE cases).<sup><xref ref-type="bibr" rid="B02">2</xref></sup>Mucin deposits have also been reported in
other DCTD such as Sj&#xF6;gren syndrome, systemic sclerosis, rheumatoid arthritis,
vasculitis and dermatomyositis.<sup><xref ref-type="bibr" rid="B03">3</xref>,<xref ref-type="bibr" rid="B04">4</xref></sup></p>
      <p>The characteristics of the primary and secondary mucinosis overlap, but the underlying
cause of the abnormal deposition of mucin is unknown.<sup><xref ref-type="bibr" rid="B02">2</xref></sup>It is suggested that in rheumatic diseases the mucinosis
could be related to circulating antibodies stimulating the synthesis of
glycosaminoglycans by skin fibroblasts. The release of cytokines is an important factor in regulating the production of
mucina.<sup><xref ref-type="bibr" rid="B03">3</xref></sup></p>
      <p>Hyaluran and chondroitin sulfate are able to activate and attract inflammatory cells,
with a resulting local increase in cytokines in vitro. Glycosaminoglycan (GAGs) are
increased in dermatomyositis and lupus skin lesions. Their involvement in the
pathophysiology of these lesions is therefore suggested.<sup><xref ref-type="bibr" rid="B05">5</xref></sup></p>
      <p>In LE, the mucin deposits may occur with or without other systemic
manifestations.<sup><xref ref-type="bibr" rid="B01">1</xref></sup>The LE chronic
plaque featuring mucin is classically known as <italic>lupus tumidus</italic>. The
lesions appear as reticular erythematous macules, papules and plaques, located
symmetrically in the center of the chest and back, and quite similar to reticular
erythematosus mucinosis (REM). However, in this form of mucinosis, the typical LE
changes in epidermis and basement membrane are absent and immunofluorescence is
negative.<sup><xref ref-type="bibr" rid="B01">1</xref></sup>In the first case we
found the typical histological findings of papular mucinosis. In the second case,
although the histology had shown mild epidermal involvement, there were no other changes
typical of LE; mucin deposition was found only in the reticular dermis, while in LE it
would have been found throughout it. These findings point to the diagnosis of reticular
mucinosis.</p>
      <p>No specific treatment exists for cutaneous mucinosis related to DCTD. Therapy is usually
directed towards the underlying disease. In idiopathic forms, numerous treatments have
already been reported, especially for the generalized forms. In Case 1 a significant
improvement was noted after increasing the azathioprine dose, and in Case 2 the response
occurred using an association of chloroquine diphosphate and prednisone. The response to
antimalarial drugs has already been mentioned in various reports and series of
cases.<sup><xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B02">2</xref>,<xref ref-type="bibr" rid="B06">6</xref>,<xref ref-type="bibr" rid="B07">7</xref></sup>In refractory cases the use of intralesional or systemic
corticosteroids could be effective, with the good response due to suppression of T
cells, keratinocytes and fibroblasts, with a consequent reduction of the proliferation
of the extracelular matrix.<sup><xref ref-type="bibr" rid="B08">8</xref></sup>Partial
regression of nodular lesions has been reported with intralesional injection of
hyaluronidase. In generalized forms thalidomide was effective in some cases and
isotretinoin has been used with good response.<sup><xref ref-type="bibr" rid="B09">9</xref>,<xref ref-type="bibr" rid="B10">10</xref></sup>Several other
immunosuppressant agents such as cyclophosphamide, melphalan and azathioprine have been
used with variable responses to severe forms, but there are no reports in localized
forms.</p>
      <p>These are the first reports of mucinosis in MCTD. In both cases, the appearance of skin
lesions occurred during good control of other underlying disease. There was a clinical
response to azathioprine in one case and to chloroquine plus prednisone in the
other.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Study conducted at the Rheumatology and Dermatology Department of the Hospital das
Cl&#xED;nicas of the Faculty of Medicine, University of S&#xE3;o Paulo (HC-FMUSP) - S&#xE3;o Paulo
(SP), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lowe</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rapini</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Golitz</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Papulonodular dermal mucinosis in lupus erythematosus</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1992</year>
          <volume>27</volume>
          <fpage>312</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="pmid">1517494</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rongioletti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rebora</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The new cutaneous mucinosis: A review with an up-to-date
classification of cutaneous mucinosis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1991</year>
          <volume>24</volume>
          <fpage>265</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="pmid">2007673</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edward</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thind</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Burden</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous mucinosis associated with dermatomyositis and nephrogenic
fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect on patient
serum</article-title>
          <source>Br J Dermatol</source>
          <year>2007</year>
          <volume>156</volume>
          <fpage>473</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="pmid">17300236</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>del Pozo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Almagro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mart&#xED;nez</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>YebraPimentel</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Garc&#xED;aSilva</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pe&#xF1;a Penabad</surname>
              <given-names>C</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Dermatomyositis and mucinosis</article-title>
          <source>Int J Dermatol</source>
          <year>2001</year>
          <volume>40</volume>
          <fpage>120</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">11328393</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Maheshwari</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Werth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schaffer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Head</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Kovarik</surname>
              <given-names>C</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Identification and Molecular Analysis of Glycosaminoglycans in
Cutaneous Lupus Erythematosus and Dermatomyositis</article-title>
          <source>J Histochem Cytochem</source>
          <year>2011</year>
          <volume>59</volume>
          <fpage>336</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">21378287</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dias</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Schetinne</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>MAS</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>IS</given-names>
            </name>
          </person-group>
          <article-title>REM syndrome associated with systemic lupus erythematosus and
hypotiroidism</article-title>
          <source>An Bras Dermatol</source>
          <year>2005</year>
          <volume>80</volume>
          <fpage>S376</fpage>
          <lpage>S379</lpage>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Recognizing and managing reticular erythematous mucinosis: comment on
"Clinical features and efficacy of antimalarial treatment for reticular
erythematous mucinosis"</article-title>
          <source>Arch Dermatol</source>
          <year>2011</year>
          <volume>147</volume>
          <fpage>715</fpage>
          <pub-id pub-id-type="pmid">21690534</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>s1dLan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Pretibial myxoedema with autoimmunity and hyperplasia treated with
glucocorticoids and surgery</article-title>
          <source>Br J Dermatol</source>
          <year>2012</year>
          <volume>166</volume>
          <fpage>457</fpage>
          <lpage>459</lpage>
          <pub-id pub-id-type="pmid">21848686</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sansbury</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Cocuroccia</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jorizzo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Gubinelli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gisondi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Girolomoni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Treatment of recalcitrant scleromyxedema with thalidomide in 3
patients</article-title>
          <source>Am Acad Dermatol</source>
          <year>2004</year>
          <volume>51</volume>
          <fpage>126</fpage>
          <lpage>131</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kanwar</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Saikia</surname>
              <given-names>UN</given-names>
            </name>
          </person-group>
          <article-title>Scleromyxoedema with disseminated subcutaneous nodules: rare
presentation of an uncommon dermatosis</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2013</year>
          <volume>38</volume>
          <fpage>36</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">22607617</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
